If approved, Vyvgart Hytrulo (efgartigimod alfa) will be the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue, muscle weakness, and loss of feeling that can lead to serious disability.
At the moment, drug treatment for CIDP relies on corticosteroids or high-dose intravenous immune globulins, such as Takeda’s Hyqvia and Gammagard Liquid, or a procedure called plasmapheresis, which involves removing patients’ blood and returning the whole cells without the plasma that contains auto-antibodies that cause the disease.
